What is the 13F Pro Quality Score for RYTM?

13F Pro ranks RHYTHM PHARMACEUTICALS, INC. (RYTM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RYTM's current score at https://13fpro.ai/company/RYTM (free sign-up required for the full ranking).

Which hedge funds own the most RYTM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BlackRock,, BAKER BROS. ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/RYTM as soon as new 13F filings post.

Where does 13F Pro source RYTM data?

All RHYTHM PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. RHYTHM PHARMACEUTICALS, INC. files with the SEC under CIK 1649904. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RYTM in?

RHYTHM PHARMACEUTICALS, INC. (RYTM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RYTM research updated on 13F Pro?

RYTM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

RHYTHM PHARMACEUTICALS, INC.(RYTM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1649904 RYTM stock profile & AI dashboard →

13F Pro Quality Score

33.9/100

Rank #2,366 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

94.6/100

Profitability

8.3/100

Balance Sheet

3.4/100

Earnings Quality

33.4/100

Free Cash Flow

10.0/100

Institutional Flow

60.6/100

Revenue Scale

26.2/100

Dilution Risk

5.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why RYTM Scores 34/100

exact factor attribution · 2026-09-11

RYTM's composite is driven by revenue growth, held back by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.9 pts

95th pct

Institutional flow

+0.5 pts

61th pct

Earnings growth

-1.2 pts

26th pct

Earnings quality

-1.7 pts

33th pct

Shareholder dilution

-2.2 pts

6th pct

Scale

-3.6 pts

26th pct

Capital efficiency

-4.7 pts

3th pct

Free cash flow

-6.0 pts

10th pct

Profitability

-6.3 pts

8th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

RYTM Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for RHYTHM PHARMACEUTICALS, INC. (RYTM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RYTM at 33.9/100 on a 32-signal composite quality model, placing it at rank #2,366 of 2,961 stocks — the bottom half of the AI-ranked universe. RYTM scores in the top quartile across revenue growth (94.6). Areas of concern include balance sheet strength (3.4) and profitability (8.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), RHYTHM PHARMACEUTICALS, INC. reports quarterly revenue of $71.3M, net income of $-49.3M, an operating margin of -68.1%. Top institutional holders of RYTM by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., BlackRock, BAKER BROS. ADVISORS, based on the most recent SEC filings. RYTM trades on the Nasdaq exchange and files with the SEC under CIK 1649904. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RYTM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RHYTHM PHARMACEUTICALS, INC. directly from SEC EDGAR. RHYTHM PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 27 and 36 since 2024, currently 33.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about RHYTHM PHARMACEUTICALS, INC.

Quirks, history, and lore behind RYTM — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Boston, Massachusetts.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, driven almost entirely by a single approved drug — a classic one-product biotech balancing act.
3
The History
Founded in the 2010s, the company focused from the start on a corner of medicine most drugmakers ignored: rare genetic diseases that cause severe, unrelenting obesity.
4
The Secret
Its target is the melanocortin-4 receptor pathway — a brain signaling system that, when broken by genetic mutation, leaves patients unable to feel full no matter how much they eat.
5
The Lore
Its approved therapy, setmelanotide, was the first drug ever cleared specifically for MC4R pathway obesity disorders, covering conditions so rare some had no treatment options for decades.
6
The Giveaway
Its very name nods to the biological rhythms disrupted by hunger-signaling mutations, and its ticker — RYTM — keeps the beat on Nasdaq.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$71.3M

Net Income

Q2 2026

$-49.3M

Operating Margin

Q2 2026

-68.1%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+45.8% YoY

$189.8MFY 2025

FY22 $23.6MFY23 $77.4MFY24 $130.1MFY25 $189.8M

Net Income

+24.6% YoY

$-196.5MFY 2025

FY22 $-181.1MFY23 $-184.7MFY24 $-260.6MFY25 $-196.5M

Operating Income

+27.7% YoY

$-192.0MFY 2025

FY22 $-179.2MFY23 $-184.4MFY24 $-265.5MFY25 $-192.0M

EPS (Diluted)

+28.3% YoY

$-3.11FY 2025

FY22 $-3.47FY23 $-3.20FY24 $-4.34FY25 $-3.11

Total Assets

+22.4% YoY

$480.2MFY 2025

FY22 $382.5MFY23 $332.7MFY24 $392.3MFY25 $480.2M

Total Debt

-1.5% YoY

$108.2MFY 2025

FY22 —FY23 $106.1MFY24 $109.8MFY25 $108.2M

Op. Cash Flow

-1.6% YoY

$-115.7MFY 2025

FY22 $-173.4MFY23 $-136.2MFY24 $-113.9MFY25 $-115.7M

Free Cash Flow

-2.4% YoY

$-116.6MFY 2025

FY22 $-173.7MFY23 $-136.2MFY24 $-113.9MFY25 $-116.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$189.8M +45.8%	$130.1M +68.1%	$77.4M +227.6%	$23.6M +649.5%	$3.2M	$0.00
Net Income	$-196.5M +24.6%	$-260.6M -41.1%	$-184.7M -2.0%	$-181.1M -160.2%	$-69.6M +48.0%	$-134.0M
Operating Income	$-192.0M +27.7%	$-265.5M -44.0%	$-184.4M -2.9%	$-179.2M -5.3%	$-170.1M -24.5%	$-136.6M
EPS (Diluted)	$-3.11 +28.3%	$-4.34 -35.6%	$-3.20 +7.8%	$-3.47 -147.9%	$-1.40 +53.9%	$-3.04
Total Assets	$480.2M +22.4%	$392.3M +17.9%	$332.7M -13.0%	$382.5M +16.1%	$329.5M +76.1%	$187.1M
Total Debt	$108.2M -1.5%	$109.8M +3.5%	$106.1M	—	—	—
Operating Cash Flow	$-115.7M -1.6%	$-113.9M +16.4%	$-136.2M +21.5%	$-173.4M -18.8%	$-146.0M -19.7%	$-122.0M
Free Cash Flow	$-116.6M -2.4%	$-113.9M +16.4%	$-136.2M +21.6%	$-173.7M -18.6%	$-146.4M -19.8%	$-122.2M

Get alerted when RYTM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for RHYTHM PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RYTM

RA CAPITAL MANAGEMENT, L.P.
$740.2M6,666,837 sh
BlackRock, Inc.
$683.6M6,156,902 sh
BAKER BROS. ADVISORS LP
$622.3M5,604,483 sh
PRIMECAP MANAGEMENT CO/CA/
$351.8M3,168,853 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$348.3M3,136,895 sh
VANGUARD CAPITAL MANAGEMENT LLC
$333.8M3,005,977 sh
JPMORGAN CHASE & CO
$292.2M2,652,746 sh
PERCEPTIVE ADVISORS LLC
$287.2M2,586,295 sh
STATE STREET CORP
$285.7M2,573,529 sh
PRICE T ROWE ASSOCIATES INC /MD/
$284.9M2,566,171 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$740.2M	6,666,837
BlackRock, Inc.	$683.6M	6,156,902
BAKER BROS. ADVISORS LP	$622.3M	5,604,483
PRIMECAP MANAGEMENT CO/CA/	$351.8M	3,168,853
VANGUARD PORTFOLIO MANAGEMENT LLC	$348.3M	3,136,895
VANGUARD CAPITAL MANAGEMENT LLC	$333.8M	3,005,977
JPMORGAN CHASE & CO	$292.2M	2,652,746
PERCEPTIVE ADVISORS LLC	$287.2M	2,586,295
STATE STREET CORP	$285.7M	2,573,529
PRICE T ROWE ASSOCIATES INC /MD/	$284.9M	2,566,171

Companies Similar to RYTM

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CYTK

CYTOKINETICS INC

AI score

Very similar · 25 shared holders

Polar Capital Holdings Plc Capital Research Global Investors Siren, L.L.C.

MIRM

Mirum Pharmaceuticals, Inc.

AI score

Very similar · 28 shared holders

Polar Capital Holdings Plc Rock Springs Capital Management LP Clearbridge Investments, LLC

KYMR

Kymera Therapeutics, Inc.

AI score

Very similar · 30 shared holders

BAKER BROS. ADVISORS LP Capital Research Global Investors Siren, L.L.C.

MDGL

MADRIGAL PHARMACEUTICALS, INC.

AI score

Very similar · 30 shared holders

BAKER BROS. ADVISORS LP Polar Capital Holdings Plc Rock Springs Capital Management LP

BBIO

BridgeBio Pharma, Inc.

AI score

Very similar · 26 shared holders

Polar Capital Holdings Plc PRIMECAP MANAGEMENT CO/CA/Clearbridge Investments, LLC

INSM

INSMED Inc

AI score

Very similar · 22 shared holders

BAKER BROS. ADVISORS LP WESTFIELD CAPITAL MANAGEMENT CO LP Polar Capital Holdings Plc

Guardant Health, Inc.

AI score

Similar quality profile · 21 shared holders

WESTFIELD CAPITAL MANAGEMENT CO LP Clearbridge Investments, LLC Artisan Partners Limited Partnership

TNGX

Tango Therapeutics, Inc.

AI score

Similar quality profile · 22 shared holders

Siren, L.L.C.PERCEPTIVE ADVISORS LLC Candriam S.C.A.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RYTM on your watchlist

Track score changes the day RHYTHM PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RYTM a good stock to buy?

13F Pro's AI-powered analysis of RHYTHM PHARMACEUTICALS, INC. (RYTM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RYTM are available on the RYTM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RYTM is classified as a mid company.

Which hedge funds own RYTM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RYTM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RHYTHM PHARMACEUTICALS, INC.'s investment landscape.